PE20210397A1 - Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cancer - Google Patents

Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cancer

Info

Publication number
PE20210397A1
PE20210397A1 PE2020001252A PE2020001252A PE20210397A1 PE 20210397 A1 PE20210397 A1 PE 20210397A1 PE 2020001252 A PE2020001252 A PE 2020001252A PE 2020001252 A PE2020001252 A PE 2020001252A PE 20210397 A1 PE20210397 A1 PE 20210397A1
Authority
PE
Peru
Prior art keywords
phenyl
membered heterocycloalkyl
carboxamide
pyrimidine
alkyl
Prior art date
Application number
PE2020001252A
Other languages
English (en)
Inventor
Jun Pan
Evan Styduhar
Qinda Ye
Alexander Sokolsky
Wenqing Yao
Oleg Vechorkin
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of PE20210397A1 publication Critical patent/PE20210397A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Referida a un compuesto de formula (I'), donde: CyA es cicloalquilo C3-12 o heterocicloalquilo de 4 a 12 miembros, donde cada heterocicloalquilo de 4 a 12 miembros tiene al menos un atomo de carbono formador de anillos y 1, 2, 3 o 4 heteroatomos formadores de anillos seleccionados de forma independiente de N, O y S, en los que N y S se encuentran opcionalmente oxidados, en los que el atomo de carbono formador de anillos del heterocicloalquilo de 4 a 12 miembros se sustituye opcionalmente con oxo para formar un grupo carbonilo, y donde cada uno del cicloalquilo C3-12 y el heterocicloalquilo de 4 a 12 miembros se encuentra opcionalmente sustituido con 1, 2, 3 o 4 sustituyentes seleccionados de forma independiente de RA; A es N o CR16; R16 se selecciona de H, D, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, halo, CN, NO2, entre otros; R1 se selecciona de H, D, halo, CN, alquilo C1-6, entre otros; R2 se selecciona de H, D, Cy2, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, halo, CN, entre otros; R4 se selecciona de forma independiente de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, haloalquilo C1-6, cicloalquilo C3-10, 10 heterocicloalquilo de 4 a 10 miembros, arilo C6-10, entre otros; n es 0, 1, 2, 3 o 4. Son compuestos preferidos: N-(2-((1R,4R)-2,5-diazabiciclo[2.2.1]heptan-2-il)-5-fluorofenil)-2-(2-fluoro-6-metoxifenil)pirimidina-4-carboxamida; (S)-N-(2-(3-aminopirrolidin-1-il)-5-fluorofenil)-2-(2-fluoro-6-metoxifenil)pirimidina-4-carboxamida; entre otros. Dichos compuestos modulan la actividad de la cinasa de progenitores hematopoyeticos 1 (HPK1) y son utiles en el tratamiento de cancer, entre otras.
PE2020001252A 2018-02-20 2019-02-19 Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cancer PE20210397A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862632702P 2018-02-20 2018-02-20
US201862672772P 2018-05-17 2018-05-17
US201862750371P 2018-10-25 2018-10-25
PCT/US2019/018608 WO2019164846A1 (en) 2018-02-20 2019-02-19 N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
PE20210397A1 true PE20210397A1 (es) 2021-03-02

Family

ID=65635851

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001252A PE20210397A1 (es) 2018-02-20 2019-02-19 Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cancer

Country Status (29)

Country Link
US (2) US10800761B2 (es)
EP (1) EP3755703B1 (es)
JP (1) JP2021515033A (es)
KR (1) KR20200133747A (es)
CN (1) CN112292380B (es)
AU (1) AU2019223955A1 (es)
BR (1) BR112020016927A2 (es)
CA (1) CA3091517A1 (es)
CL (1) CL2020002146A1 (es)
CO (1) CO2020011530A2 (es)
CR (1) CR20200421A (es)
DK (1) DK3755703T3 (es)
EC (1) ECSP20058964A (es)
ES (1) ES2922237T3 (es)
HR (1) HRP20220833T1 (es)
HU (1) HUE059624T2 (es)
IL (1) IL276779B2 (es)
LT (1) LT3755703T (es)
MD (1) MD3755703T2 (es)
MX (1) MX2020008656A (es)
PE (1) PE20210397A1 (es)
PH (1) PH12020551278A1 (es)
PL (1) PL3755703T3 (es)
PT (1) PT3755703T (es)
RS (1) RS63659B1 (es)
SG (1) SG11202007917VA (es)
SI (1) SI3755703T1 (es)
TW (1) TWI828653B (es)
WO (1) WO2019164846A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049152A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
EP3510032B1 (en) 2016-09-09 2022-07-06 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
CA3091517A1 (en) 2018-02-20 2019-08-29 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
WO2020068729A1 (en) 2018-09-25 2020-04-02 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators
TWI721624B (zh) 2018-10-31 2021-03-11 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
CN113227089A (zh) 2018-10-31 2021-08-06 吉利德科学公司 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
MA54546A (fr) * 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
MX2022001562A (es) * 2019-08-06 2022-04-26 Incyte Corp Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
EP4288437A1 (en) 2021-02-05 2023-12-13 Bayer Aktiengesellschaft Map4k1 inhibitors
TW202321239A (zh) 2021-07-20 2023-06-01 瑞典商阿斯特捷利康公司 作為ｈｐｋ１抑制劑用於治療癌症之經取代的吡𠯤—２—甲醯胺

Family Cites Families (242)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8800613D0 (sv) 1988-02-23 1988-02-23 Wallac Oy A novel spectrofluorometric method and compounds that are of value for the method
JPH03287584A (ja) 1990-04-05 1991-12-18 Banyu Pharmaceut Co Ltd 置換アリルアミン誘導体
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
BR9810233A (pt) 1997-04-25 2000-10-17 Pfizer Pirozolpirimidinonas que inibem fosfodiesterase da guanosina 3`, 5`- monosfofato cìclico do tipo 5 (cgmp pde5) para o tratamento da disfunção sexual.
EP1073658B1 (en) 1998-04-20 2003-08-13 Pfizer Inc. Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
IN187433B (es) 1999-09-10 2002-04-27 Cipla Ltd
AU1888800A (en) 1999-09-13 2001-04-17 Cipla Limited A novel process for the synthesis of sildenafil citrate
CZ2002934A3 (cs) 1999-09-17 2002-07-17 Abbott Gmbh & Co. Kg Inhibitory kinázy jako terapeutická činidla
US6864289B1 (en) 1999-09-24 2005-03-08 Nihon Nohyaku Co., Ltd. Aromatic diamide derivatives or salts thereof, agricultural/horticultural chemicals and method of using the same
CZ20021151A3 (cs) 1999-10-11 2003-03-12 Pfizer Inc. 5-(2-substituovaný-5-heterocyklylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]-pyrimidin-7-ony jako inhibitory fosfodiesterasy
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
IL152925A (en) 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
EP1241159A4 (en) 1999-12-22 2006-03-01 Nihon Nohyaku Co Ltd DERIVATIVES OF AROMATIC DIAMIDES, CHEMICALS FOR APPLICATION TO AGRICULTURE AND GARDENING AND THEIR USE
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
AU1560802A (en) 2000-06-28 2002-01-08 Smithkline Beecham Plc Wet milling process
WO2002016348A1 (en) 2000-08-09 2002-02-28 Astrazeneca Ab Antiangiogenic bicyclic derivatives
WO2002019975A1 (fr) 2000-09-05 2002-03-14 Taisho Pharmaceutical Co., Ltd. Stimulants de la croissance des cheveux
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US7105532B2 (en) 2000-12-19 2006-09-12 Smithkline Beecham Corporation Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors
MXPA03005393A (es) 2000-12-19 2003-09-25 Merck Patent Gmbh Formulacion farmaceutica que contiene pirazolo (4,3-d) pirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina.
US6770645B2 (en) 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
US6784185B2 (en) 2001-03-16 2004-08-31 Pfizer Inc. Pharmaceutically active compounds
EP1396493A4 (en) 2001-04-26 2005-08-03 Ajinomoto Kk HETEROCYCLIC COMPOUNDS
JP2004532856A (ja) 2001-04-30 2004-10-28 藤沢薬品工業株式会社 アポリポタンパク質ｂ阻害剤としてのビアリールカルボキサミド化合物
FR2825706B1 (fr) 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
JP2005508978A (ja) 2001-11-02 2005-04-07 ファイザー・プロダクツ・インク Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療
TW200303201A (en) 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
US7166293B2 (en) 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
US20050119278A1 (en) 2002-05-16 2005-06-02 Che-Ming Teng Anti-angiogenesis methods
IL164209A0 (en) 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
CA2515571A1 (en) 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
DE602004024375D1 (de) 2003-02-14 2010-01-14 Glaxo Group Ltd Carboxamidderivate
EP1613747A1 (en) 2003-03-31 2006-01-11 Pfizer Products Inc. Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
JP4015176B2 (ja) 2003-04-29 2007-11-28 ファイザー・インク 高血圧症の治療に有用な５，７−ジアミノピラゾロ４，３−ジピリミジン類
WO2004108133A2 (en) 2003-06-05 2004-12-16 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
JP2007505950A (ja) 2003-06-10 2007-03-15 フルクラム・ファーマシューティカルズ・インコーポレーテッド β−ラクタマーゼ阻害剤およびその使用方法
JP2007500700A (ja) 2003-07-29 2007-01-18 スミスクライン ビーチャム コーポレーション 化合物
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
US7772234B2 (en) 2003-11-19 2010-08-10 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
US20050137398A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-Quinuclidinyl heteroatom bridged biaryl derivatives
US7241773B2 (en) 2003-12-22 2007-07-10 Abbott Laboratories 3-quinuclidinyl heteroatom bridged biaryl derivatives
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
DE102004005172A1 (de) 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
EP1720878A1 (en) 2004-02-27 2006-11-15 F.Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
CA2557575A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole
WO2005085227A1 (en) 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
TW200618800A (en) 2004-08-03 2006-06-16 Uriach Y Compania S A J Heterocyclic compounds
US7888364B2 (en) 2004-09-02 2011-02-15 Curis, Inc. Pyridyl inhibitors of hedgehog signalling
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
EP2332527A3 (en) 2004-10-20 2011-11-16 Resverlogix Corp. Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
JP2008518926A (ja) 2004-10-28 2008-06-05 ジ インスティチューツ フォー ファーマシューティカル ディスカバリー、エルエルシー 置換フェニルアルカン酸
AU2005304393B2 (en) 2004-11-10 2012-09-27 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
MX2007005643A (es) 2004-11-10 2008-03-13 Cgi Pharmaceuticals Inc Ciertas imidazo [1,2-a] pirazin-8-ilaminas, metodo para su elaboracion y metodo de uso de las mismas.
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
CN100516049C (zh) 2004-11-16 2009-07-22 永信药品工业股份有限公司 抗血管生成药n2-(取代的芳基甲基)-3-(取代的苯基)吲唑的合成
KR20070115879A (ko) 2005-01-07 2007-12-06 에모리 유니버시티 의학 장애의 치료용 ｃｘｃｒ4 길항제
MX2007012234A (es) 2005-03-31 2008-03-18 Johnson & Johnson Compuestos de pirazol biciclico como agentes antibacterianos.
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
AU2006278396A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
GB0516703D0 (en) 2005-08-15 2005-09-21 Syngenta Participations Ag Novel insecticides
JP2007055940A (ja) 2005-08-24 2007-03-08 Astellas Pharma Inc ピラゾロピリミジン誘導体
JP2009506006A (ja) 2005-08-25 2009-02-12 エフ．ホフマン−ラ ロシュ アーゲー ｐ３８ＭＡＰキナーゼ阻害剤およびその使用方法
EP1919918A2 (en) 2005-08-25 2008-05-14 F.Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
MX2008002587A (es) 2005-08-25 2008-03-18 Hoffmann La Roche Inhibidores de la p38-map-cinasa y metodos para el uso de los mismos.
WO2007030582A2 (en) 2005-09-09 2007-03-15 Bristol-Myers Squibb Company Acyclic ikur inhibitors
US20070087988A1 (en) 2005-09-30 2007-04-19 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
WO2007114848A2 (en) 2005-10-25 2007-10-11 Smithkline Beecham Corporation Chemical compounds
WO2007056280A1 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors
WO2007063925A1 (ja) 2005-11-30 2007-06-07 Astellas Pharma Inc. ２－アミノベンズアミド誘導体
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
KR20080083188A (ko) 2006-01-11 2008-09-16 아스트라제네카 아베 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
EP1984354B1 (en) 2006-02-16 2009-08-05 Syngeta Participations AG Pesticides containing a bicyclic bisamide structure
AU2007230911A1 (en) 2006-03-23 2007-10-04 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
BRPI0710107A2 (pt) 2006-03-30 2011-08-02 Irm Llc composto, composição compreendendo o mesmo, bem como uso do mesmo
CN101448825A (zh) 2006-05-19 2009-06-03 艾博特公司 Cns活性的稠合的双环杂环取代的氮杂双环烷烃衍生物
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
GB0614691D0 (en) 2006-07-24 2006-08-30 Syngenta Participations Ag Insecticidal compounds
CA2664147A1 (en) 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
AU2007329728A1 (en) 2006-10-20 2008-06-12 Concert Pharmaceuticals Inc. 3-(dihydro-1H-pyrazolo (4,3-d) pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
KR101514853B1 (ko) * 2007-03-01 2015-04-24 노파르티스 아게 Ｐｉｍ 키나제 억제제 및 이들의 사용 방법
US20140249135A1 (en) * 2007-03-01 2014-09-04 Novartis Ag Pim kinase inhibitors and methods of their use
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
JP5241834B2 (ja) * 2007-07-19 2013-07-17 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としての複素環アミド化合物
MY146643A (en) 2007-07-30 2012-09-14 Dae Woong Pharma Novel benzoimidazole derivatives and pharmaceutical composition comprising the same
AU2008285722B2 (en) 2007-08-08 2013-06-20 Merck Serono S.A. 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis
GB0716414D0 (en) 2007-08-22 2007-10-03 Syngenta Participations Ag Novel insecticides
WO2009032651A1 (en) 2007-08-31 2009-03-12 Smithkline Beecham Corporation Inhibitors of akt activity
US8314131B2 (en) 2007-09-21 2012-11-20 Amgen Inc. Triazole fused heteroaryl compounds and methods of use thereof
JP2011502984A (ja) * 2007-11-01 2011-01-27 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターとしてのアミド誘導体
KR100963644B1 (ko) 2007-11-23 2010-06-15 한국과학기술연구원 피라졸로피리미딘온 유도체 및 그의 제조방법
CA2714181C (en) 2008-02-04 2013-12-24 Mercury Therapeutics, Inc. Ampk modulators
EP2273882A4 (en) 2008-05-13 2011-07-13 Poniard Pharmaceuticals Inc BIOACTIVE COMPOUNDS FOR THE TREATMENT OF CANCER AND NEURODEEGENERATIVE DISEASES
BRPI0915205A2 (pt) 2008-06-11 2017-03-21 Dana Farber Cancer Inst Inc compostos e composições úteis para o tratamento de malária
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2010029300A1 (en) 2008-09-12 2010-03-18 Biolipox Ab Bis aromatic compounds for use in the treatment of inflammation
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
US8232273B2 (en) 2008-12-19 2012-07-31 Genentech, Inc. Heterocyclic compounds and methods of use
WO2010104306A2 (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
AU2010226826A1 (en) 2009-03-18 2011-10-13 Merck Sharp & Dohme Corp. Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
EP2411328B1 (en) 2009-03-26 2019-07-24 Northeastern University Carbon nanostructures from pyrolysis of organic materials
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
WO2011019780A1 (en) 2009-08-11 2011-02-17 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
EP2477498A4 (en) 2009-09-14 2013-02-27 Merck Sharp & Dohme DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
ES2360333B1 (es) 2009-10-29 2012-05-04 Consejo Superior De Investigaciones Cientificas (Csic) (70%) Derivados de bis (aralquil) amino y sistemas (hetero) aromaticos de seis miembros y su uso en el tratamiento de patologias neurodegenerativas, incluida la enfermedad de alzheimer
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
AR079975A1 (es) 2010-01-06 2012-03-07 British Columbia Cancer Agency Agentes terapeuticos derivados de bisfenol u metodos para su uso, composiciones farmaceuticas y uso de los mismos
DE102010009903A1 (de) 2010-03-02 2011-09-08 Merck Patent Gmbh Verbindungen für elektronische Vorrichtungen
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
PT2563776T (pt) 2010-04-27 2016-09-19 Calcimedica Inc Compostos que modulam o cálcio intracelular
GB201008134D0 (en) 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
JP2011246389A (ja) 2010-05-26 2011-12-08 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体
ES2660611T3 (es) 2010-05-27 2018-03-23 Bayer Cropscience Ag Derivados de ácido piridinilcarboxílico como fungicidas
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
KR20130087495A (ko) 2010-06-15 2013-08-06 바이엘 인텔렉쳐 프로퍼티 게엠베하 안트라닐산 유도체
WO2011158108A2 (en) 2010-06-16 2011-12-22 Purdue Pharma L.P. Aryl substituted indoles and the use thereof
US8987273B2 (en) 2010-07-28 2015-03-24 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-B]pyridazines
JP5844376B2 (ja) 2010-10-06 2016-01-13 ジェイファーマ株式会社 強力な尿酸トランスポーター阻害剤の開発：それらの尿酸***効果のために設計された化合物
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
CA2819373A1 (en) 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
AR084308A1 (es) 2010-12-17 2013-05-08 Syngenta Participations Ag Compuestos insecticidas derivados de triazol
SG191844A1 (en) 2011-01-04 2013-08-30 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
ES2732311T3 (es) 2011-02-07 2019-11-21 Univ Washington Compuestos de manósidos y procedimientos de uso de los mismos
WO2012130780A1 (en) 2011-03-28 2012-10-04 F. Hoffmann-La Roche Ag Thiazolopyrimidine compounds
KR101442644B1 (ko) 2011-04-12 2014-09-19 주식회사 종근당 Ｃｅｔｐ 억제제로서의 사이클로알케닐 아릴 유도체
SG194549A1 (en) 2011-04-21 2013-12-30 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
US9328075B2 (en) * 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
WO2012156367A1 (en) 2011-05-17 2012-11-22 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
WO2012158810A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Tyrosine kinase inhibitors
TW201311677A (zh) 2011-05-31 2013-03-16 Syngenta Participations Ag 殺蟲化合物
US9730929B2 (en) 2011-06-01 2017-08-15 Bayer Intellectual Property Gmbh Substituted aminoimidazopyridazines
JP5944497B2 (ja) 2011-06-22 2016-07-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ヘテロシクリルアミノイミダゾピリダジン
EP2543372A1 (en) 2011-07-08 2013-01-09 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for the treatment of liver cancer
WO2013007708A1 (en) 2011-07-08 2013-01-17 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
WO2013021276A1 (en) 2011-08-10 2013-02-14 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
CN103874700B (zh) 2011-08-12 2018-03-30 霍夫曼-拉罗奇有限公司 吡唑并[3,4‑c]吡啶化合物和使用方法
CN103889976A (zh) 2011-08-12 2014-06-25 弗·哈夫曼-拉罗切有限公司 吲唑化合物、组合物及使用方法
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
US9320737B2 (en) 2011-09-23 2016-04-26 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
CN102503959B (zh) 2011-10-25 2015-04-08 南方医科大学 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN102516263B (zh) 2011-10-25 2015-04-08 南方医科大学 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CA2849194A1 (en) 2011-11-01 2013-05-10 F. Hoffmann-La Roche Ag Imidazopyridazine compounds
CA2864484C (en) 2012-02-17 2019-07-02 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
JP6101248B2 (ja) 2012-03-28 2017-03-22 出光興産株式会社 新規化合物、有機エレクトロルミネッセンス素子用材料および有機エレクトロルミネッセンス素子
KR20150002573A (ko) 2012-04-20 2015-01-07 길리애드 사이언시즈, 인코포레이티드 벤조티아졸-6-일 아세트산 유도체 및 ｈｉｖ 감염을 치료하기 위한 이의 용도
WO2014003405A1 (ko) 2012-06-26 2014-01-03 주식회사 제이앤드제이 캐미칼 신규한 화합물 및 이를 포함하는 발광소자
EA201590118A1 (ru) 2012-06-28 2015-04-30 Новартис Аг Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
KR101936851B1 (ko) 2012-07-16 2019-01-11 한국과학기술연구원 단백질 키나아제 저해제인 신규 피라졸로피리딘 유도체 또는 인다졸 유도체
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
TW201412744A (zh) 2012-08-23 2014-04-01 Mitsubishi Tanabe Pharma Corp 吡唑并嘧啶化合物
KR102124227B1 (ko) 2012-09-24 2020-06-17 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 금속 화합물, 방법, 및 이의 용도
SG11201502527UA (en) 2012-10-05 2015-04-29 Rigel Pharmaceuticals Inc Gdf-8 inhibitors
KR102137472B1 (ko) 2013-02-08 2020-07-27 삼성디스플레이 주식회사 유기 발광 소자
EP2968304B1 (en) 2013-03-14 2018-10-10 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
US8853278B1 (en) 2013-05-22 2014-10-07 Curza Global, Llc Compositions comprising a biocidal polyamine
CN104232076B (zh) 2013-06-10 2019-01-15 代表亚利桑那大学的亚利桑那校董会 具有改进的发射光谱的磷光四齿金属络合物
EP3035800B1 (en) 2013-08-22 2019-10-09 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
WO2015037965A1 (en) 2013-09-16 2015-03-19 Rohm And Haas Electronic Materials Korea Ltd. Novel organic electroluminescent compounds and organic electroluminescent device comprising the same
AU2014337067B2 (en) 2013-10-18 2019-01-24 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
LT3060550T (lt) 2013-10-21 2019-08-12 Merck Patent Gmbh Heteroarilo junginiai, kaip btk inhibitoriai, ir jų panaudojimas
ES2713196T3 (es) 2013-12-11 2019-05-20 Biogen Ma Inc Compuestos de biarilo útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
CA2932351A1 (en) 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
WO2015090235A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use thereof
MX2016009011A (es) 2014-01-10 2017-01-23 Aurigene Discovery Tech Ltd Compuestos de indazol como inhibidores de cinasa-4 asociada al receptor de interleucina-1 (irak4).
KR102349550B1 (ko) 2014-02-05 2022-01-11 메르크 파텐트 게엠베하 금속 착물
CN112250673A (zh) 2014-02-25 2021-01-22 艾其林医药公司 用于治疗补体介导疾病的芳基、杂芳基和杂环化合物
US9871208B2 (en) 2014-02-26 2018-01-16 Samsung Display Co., Ltd. Condensed cyclic compound and organic light-emitting device including the same
WO2015164956A1 (en) 2014-04-29 2015-11-05 The University Of British Columbia Benzisothiazole derivative compounds as therapeutics and methods for their use
US20150328188A1 (en) 2014-05-19 2015-11-19 Everardus O. Orlemans Combination Therapies for the Treatment of Proliferative Disorders
EP3158597B1 (de) 2014-06-18 2020-09-23 Merck Patent GmbH Materialien für organische elektrolumineszenzvorrichtungen
EA201692418A1 (ru) 2014-06-20 2017-04-28 Ауриджен Дискавери Текнолоджиз Лимитед Замещенные индазольные соединения в качестве irak4 ингибиторов
EP3157904B1 (en) 2014-06-20 2020-11-18 Institut Pasteur Korea Anti-infective compounds
WO2015200682A1 (en) 2014-06-25 2015-12-30 Vanderbilt University Substituted 4-alkoxypicolinamide analogs ds mglur5 negative allosteric modulators
KR20160007967A (ko) 2014-07-10 2016-01-21 삼성디스플레이 주식회사 유기 발광 소자
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016041618A1 (en) 2014-09-15 2016-03-24 Merck Patent Gmbh Substituted indazoles and related heterocycles
BR112017006305B1 (pt) 2014-10-06 2024-02-20 Merck Patent Gmbh Compostos heteroarila, seus usos, e composição farmacêutica
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
JP2017537929A (ja) 2014-12-05 2017-12-21 ジェネンテック， インコーポレイテッド Ｐｄ−１軸アンタゴニスト及びｈｐｋ１アンタゴニストを用いたがん治療のための方法及び組成物
WO2016124304A1 (de) 2015-02-03 2016-08-11 Merck Patent Gmbh Metallkomplexe
CN107624110B (zh) 2015-03-06 2021-01-26 法玛克亚公司 赖氨酰氧化酶样2抑制剂及其用途
CN112679467A (zh) 2015-03-11 2021-04-20 Fmc公司 杂环取代的二环唑杀有害生物剂
WO2016161571A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Indazole and azaindazole btk inhibitors
CN107872977B (zh) 2015-04-30 2021-07-09 拜耳制药股份公司 Irak4抑制剂与btk抑制剂的组合产品
SG10202105964RA (en) * 2015-06-25 2021-07-29 Univ Health Network Hpk1 inhibitors and methods of using same
CN108024971A (zh) 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的取代的氮杂化合物
BR112018000624A2 (pt) 2015-07-15 2018-09-18 Aurigene Discovery Technologies Limited compostos de indazol e azaindazol como inibidores de irak-4
WO2017023894A1 (en) 2015-08-03 2017-02-09 Raze Therapeutics, Inc. Mthfd2 inhibitors and uses thereof
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
DK3331525T3 (da) 2015-08-07 2020-12-14 Calcimedica Inc Anvendelse af CRAC-kanal-inhibitorer til behandling af slagtilfælde og traumatisk hjerneskade
WO2017045955A1 (en) 2015-09-14 2017-03-23 Basf Se Heterobicyclic compounds
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017108744A1 (de) 2015-12-22 2017-06-29 Bayer Pharma Aktiengesellschaft Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
EP3399968B8 (en) 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
JP6680953B2 (ja) 2016-07-19 2020-04-15 アーサー バーナード カミングス 人工調節型レンズ複合体
CN108602802B (zh) 2016-07-26 2020-01-21 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
EP3510032B1 (en) * 2016-09-09 2022-07-06 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049152A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
CA3091517A1 (en) 2018-02-20 2019-08-29 Incyte Corporation N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
RU2762557C1 (ru) 2018-04-26 2021-12-21 Пфайзер Инк. Производные 2-аминопиридина или 2-аминопиримидина в качестве циклинзависимых ингибиторов киназы
TWI707865B (zh) 2018-05-04 2020-10-21 丹麥商諾佛 儂迪克股份有限公司 Gip衍生物及其用途
SG11202010679SA (en) 2018-05-17 2020-11-27 Bayer Ag Substituted dihydropyrazolo pyrazine carboxamide derivatives
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
MX2022001562A (es) 2019-08-06 2022-04-26 Incyte Corp Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).

Also Published As

Publication number Publication date
PL3755703T3 (pl) 2022-11-07
EP3755703B1 (en) 2022-05-04
CA3091517A1 (en) 2019-08-29
DK3755703T3 (da) 2022-06-27
SI3755703T1 (sl) 2022-11-30
IL276779B1 (en) 2023-12-01
EP3755703A1 (en) 2020-12-30
TW201934548A (zh) 2019-09-01
US10800761B2 (en) 2020-10-13
AU2019223955A1 (en) 2020-10-08
HUE059624T2 (hu) 2022-11-28
WO2019164846A1 (en) 2019-08-29
MX2020008656A (es) 2020-12-09
JP2021515033A (ja) 2021-06-17
BR112020016927A2 (pt) 2020-12-15
US11731958B2 (en) 2023-08-22
IL276779A (en) 2020-10-29
KR20200133747A (ko) 2020-11-30
US20210094934A1 (en) 2021-04-01
IL276779B2 (en) 2024-04-01
ES2922237T3 (es) 2022-09-12
CO2020011530A2 (es) 2020-12-10
MD3755703T2 (ro) 2022-10-31
PH12020551278A1 (en) 2021-07-05
CN112292380A (zh) 2021-01-29
CR20200421A (es) 2021-01-26
TWI828653B (zh) 2024-01-11
HRP20220833T1 (hr) 2022-10-28
SG11202007917VA (en) 2020-09-29
CL2020002146A1 (es) 2021-01-29
CN112292380B (zh) 2024-04-05
RS63659B1 (sr) 2022-11-30
PT3755703T (pt) 2022-08-16
US20190382380A1 (en) 2019-12-19
ECSP20058964A (es) 2020-12-31
LT3755703T (lt) 2022-10-10

Similar Documents

Publication Publication Date Title
PE20210397A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cancer
AR109596A1 (es) Compuestos pirazolopiridina y sus usos
AR109595A1 (es) Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20212247A1 (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos
PE20150339A1 (es) Carboxamidas heterociclicas fungicidas
AR066331A1 (es) Piridonacarboxamidas agentes protectores de plantas utiles que contienen a estas y procedimientos para su preparacion y su utilizacion
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
AR051290A1 (es) Derivados de hidantoina sustituidas
PE20181853A1 (es) 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
PE20190653A1 (es) Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20170947A1 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
AR061419A1 (es) Compuestos de piridil amida sustituidos como moduladores del receptor de histamida h3
AR079541A1 (es) Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms
AR067413A1 (es) Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
AR048789A1 (es) Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
AR071531A1 (es) Compuesto cristalino heteromonociclico
AR089424A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
EA201990904A1 (ru) 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
PE20091444A1 (es) Derivados de isoxazolo-pirazina
AR106070A1 (es) Benzamidas sustituidas con isoxazolina como insecticidas
AR100713A1 (es) Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor
PE20221461A1 (es) Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr